M&A

Sanofi Gets Into Generics Game

Sanofi-Aventis plans to make a $2.57 billion (10% premium) offer for Czech generic drugmaker Zentiva, trumping a bid from financial group PPF. Sanofi’s move on Zentiva follows Daiichi Sankyo’s $4.6B offer for India’s top generic company, Ranbaxy.

Generic drug production has traditionally been shunned by large pharmaceutical companies but is now receiving increased interest as a way to tap booming emerging markets.

I’m a huge fan of diversification, especially in an industry where there is nearly none. I’d be really surprised not to see more of these deals in the next few years. There is just too much upside for big pharma not to act, but then again, cutting off the nose to spite the face isn’t a foreign concept in this industry.

Theoretically Related Posts

• September 10, 2008 -- ImClone Throws Down and Announces Additional Suitor (0)
• June 11, 2008 -- Daiichi Sankyo Goes Generic with Ranbaxy Purchase (0)
• June 10, 2008 -- TEVA Gets Taste of Own Medicine (0)
• October 30, 2008 -- GlaxoSmithKline to acquires Genelabs Technologies for $57M (0)
• October 23, 2008 -- No Rumors For You. Come Back. One Year (0)
• October 3, 2008 -- Swami Predicts ImClone’s Future (1)
• September 2, 2008 -- Shionogi Acquires Sciele Pharma for $1.4 Billion (0)
• August 22, 2008 -- Alpharma Responds to Unsolicited Proposal by King (0)
• August 22, 2008 -- King Tenders All Cash $1.4B Unsolicited Bid For Alphama (0)
• August 13, 2008 -- Genentech Drops The Other Shoe (0)

© 2008 Pharmababble.